156 related articles for article (PubMed ID: 34208089)
1. Real World Outcomes and Hepatotoxicity of Infliximab in the Treatment of Steroid-Refractory Immune-Related Adverse Events.
Araujo DV; Muniz TP; Yang A; Keshavarzi S; Sorotsky H; Butler MO; Saibil S; Spreafico A; Hogg D
Curr Oncol; 2021 Jun; 28(3):2173-2179. PubMed ID: 34208089
[TBL] [Abstract][Full Text] [Related]
2. Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab.
Zhang HC; Luo W; Wang Y
J Immunother Cancer; 2019 Feb; 7(1):47. PubMed ID: 30777137
[TBL] [Abstract][Full Text] [Related]
3. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
Harvey C; Nahar KJ; McKeown J; Lo SN; Farag S; Yousaf N; Young K; Tas L; Meerveld-Eggink A; Blank C; Thomas A; McQuade J; Schilling B; Johnson DB; Huertas RM; Arance A; Lee J; Zimmer L; Long GV; Carlino MS; Wang Y; Menzies AM
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296594
[TBL] [Abstract][Full Text] [Related]
4. Infliximab-induced liver injury: Clinical phenotypes, autoimmunity and the role of corticosteroid treatment.
Björnsson HK; Gudbjornsson B; Björnsson ES
J Hepatol; 2022 Jan; 76(1):86-92. PubMed ID: 34487751
[TBL] [Abstract][Full Text] [Related]
5. Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management.
Huffman BM; Kottschade LA; Kamath PS; Markovic SN
Am J Clin Oncol; 2018 Aug; 41(8):760-765. PubMed ID: 28749795
[TBL] [Abstract][Full Text] [Related]
6. Management of Steroid-Refractory Gastrointestinal Immune-Related Adverse Events.
Brongiel S; Rychalsky KL; Luon D; Johnson AR; Price C; Abdelghany O
Ann Pharmacother; 2023 Feb; 57(2):148-155. PubMed ID: 35656843
[TBL] [Abstract][Full Text] [Related]
7. Corticosteroid-resistant immune-related adverse events: a systematic review.
Daetwyler E; Wallrabenstein T; König D; Cappelli LC; Naidoo J; Zippelius A; Läubli H
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233099
[TBL] [Abstract][Full Text] [Related]
8. Ipilimumab-induced toxicities and the gastroenterologist.
Cheng R; Cooper A; Kench J; Watson G; Bye W; McNeil C; Shackel N
J Gastroenterol Hepatol; 2015 Apr; 30(4):657-66. PubMed ID: 25641691
[TBL] [Abstract][Full Text] [Related]
9. Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors.
Romanski NA; Holmstroem RB; Ellebaek E; Svane IM
Eur J Cancer; 2020 May; 130():211-218. PubMed ID: 32229418
[TBL] [Abstract][Full Text] [Related]
10. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
[TBL] [Abstract][Full Text] [Related]
11. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade.
Stroud CR; Hegde A; Cherry C; Naqash AR; Sharma N; Addepalli S; Cherukuri S; Parent T; Hardin J; Walker P
J Oncol Pharm Pract; 2019 Apr; 25(3):551-557. PubMed ID: 29207939
[TBL] [Abstract][Full Text] [Related]
12. Methotrexate for induction of remission in refractory Crohn's disease.
McDonald JW; Tsoulis DJ; Macdonald JK; Feagan BG
Cochrane Database Syst Rev; 2012 Dec; 12():CD003459. PubMed ID: 23235598
[TBL] [Abstract][Full Text] [Related]
13. An Investigation of Nine Patients with Gastrointestinal Immune-Related Adverse Events Caused by Immune Checkpoint Inhibitors.
Miyahara K; Noda T; Ito Y; Hidaka H; Fujimoto S; Takedomi H; Akutagawa T; Sakata Y; Shimamura T; Tominaga N; Yamaguchi D; Fujimoto K
Digestion; 2020; 101(1):60-65. PubMed ID: 31801131
[TBL] [Abstract][Full Text] [Related]
14. When steroids are not enough in immune-related hepatitis: current clinical challenges discussed on the basis of a case report.
Ziogas DC; Gkoufa A; Cholongitas E; Diamantopoulos P; Anastasopoulou A; Ascierto PA; Gogas H
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33144335
[TBL] [Abstract][Full Text] [Related]
15. Elevated liver enzymes in inflammatory bowel disease: the role and safety of infliximab.
Parisi I; O'Beirne J; Rossi RE; Tsochatzis E; Manousou P; Theocharidou E; Hamilton M; Murray C; Epstein O; Burroughs AK
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):786-91. PubMed ID: 27015138
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of immunotherapy-related hepatotoxicity from a multi-disciplinary toxicity team.
Fan C; Kim A; Li S; Naidoo J; Cappelli LC; Brahmer JR; Anders RA; Kim AK
J Cancer Res Clin Oncol; 2023 Feb; 149(2):877-883. PubMed ID: 36102989
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study.
Abu-Sbeih H; Ali FS; Alsaadi D; Jennings J; Luo W; Gong Z; Richards DM; Charabaty A; Wang Y
J Immunother Cancer; 2018 Dec; 6(1):142. PubMed ID: 30518410
[TBL] [Abstract][Full Text] [Related]
18. Myalgia and Arthralgia Immune-related Adverse Events (irAEs) in Patients With Genitourinary Malignancies Treated With Immune Checkpoint Inhibitors.
Ornstein MC; Calabrese C; Wood LS; Kirchner E; Profusek P; Allman KD; Martin A; Kontzias A; Grivas P; Garcia JA; Calabrese LH; Rini BI
Clin Genitourin Cancer; 2019 Jun; 17(3):177-182. PubMed ID: 30824360
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with etanercept in a patient with hepatotoxicity closely related to infliximab.
García Aparicio AM; Rey JR; Sanz AH; Alvarez JS
Clin Rheumatol; 2007 May; 26(5):811-3. PubMed ID: 16550301
[TBL] [Abstract][Full Text] [Related]
20. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H
J Immunother Cancer; 2018 Sep; 6(1):85. PubMed ID: 30176946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
